Skip to main content

Table 1 72 hr IC 50 for AI and adherent OS cells in the presence of doxorubicin or cisplatin

From: Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling

   Doxorubicin Cisplatin
Cell type Mean IC50 (uM) Fold change Mean IC50 (uM) Fold change
MS206-2 Adherent 0.062 ± 0.01 28.8^ 4.38 ± 0.98 5.7^
AI 1.79 ± 0.4 25.2 ± 6.9
143B Adherent 0.025 ± 0.01 13* 1.97 ± 0.19 1.9*
AI 0.31 ± 0.1 3.12 ± 0.10
mHOS Adherent 0.085 ± 0.013 35* 3.10 ± 0.53 6.9*
AI 2.97 ± 1.9 21.4 ± 10.
MG-63 Adherent 0.13 ± 0.06 >75# 2.68 ± 1.6 6.2*
AI >50% survival 16.9 ± 5.4
  1. ^Indicates p < 0.05 (two-tailed two-sample t-test).
  2. *Indicates p < 0.05 (wilcoxon signed-rank test).
  3. #Indicates >50% cell viability after treatment, so we could not calculate an IC50.